Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / interferon

interferon

UT Southwestern scientists discover ancient viral DNA activates blood cell production during pregnancy
Biotechnology | Genomics | Stem Cell | Therapeutics | Women's Health

UT Southwestern scientists discover ancient viral DNA activates blood cell production during pregnancy

On Oct. 24, 2024, researchers from Children’s Medical Center Research Institute at UT Southwestern reported that ancient viral remnants…

Read More UT Southwestern scientists discover ancient viral DNA activates blood cell production during pregnancyContinue

U.S. Preventive Services Task Force recommended screening for latent tuberculosis infection
Life Science History

U.S. Preventive Services Task Force recommended screening for latent tuberculosis infection

On May 2, 2023, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening…

Read More U.S. Preventive Services Task Force recommended screening for latent tuberculosis infectionContinue

Eiger’s single-dose Peginterferon Lambda for COVID-19 reduced risk of hospitalization or ER visits by 50% in vaccinated population
COVID-19 | Life Science History | Vaccine

Eiger’s single-dose Peginterferon Lambda for COVID-19 reduced risk of hospitalization or ER visits by 50% in vaccinated population

On Mar. 17, 2022, Eiger BioPharmaceuticals announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations…

Read More Eiger’s single-dose Peginterferon Lambda for COVID-19 reduced risk of hospitalization or ER visits by 50% in vaccinated populationContinue

Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19
COVID-19 | Life Science History

Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19

On Oct. 18, 2021, a NIAID sponsored clinical trial found that treatment with the immunomodulator interferon beta-1a plus…

Read More Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19Continue

Eiger BioPharma announced interim analysis of dosing of Peginterferon Lambda in phase 3 TOGETHER study
COVID-19 | Life Science History

Eiger BioPharma announced interim analysis of dosing of Peginterferon Lambda in phase 3 TOGETHER study

On Sept. 20, 2021, Eiger BioPharmaceuticals announced announced that Peginterferon Lambda (Lambda) will be added to the ongoing,…

Read More Eiger BioPharma announced interim analysis of dosing of Peginterferon Lambda in phase 3 TOGETHER studyContinue

Misdirected antibodies linked to severe COVID-19
COVID-19 | Life Science History | NIH

Misdirected antibodies linked to severe COVID-19

On Sept. 14, 2021, the NIH announced that an international project called the COVID Human Genetic Effort has…

Read More Misdirected antibodies linked to severe COVID-19Continue

Eiger announced Peginterferon Lambda added to multi-center phase 3 TOGETHER COVID-19 study in Brazil
COVID-19 | Life Science History

Eiger announced Peginterferon Lambda added to multi-center phase 3 TOGETHER COVID-19 study in Brazil

On May 3, 2021, Eiger BioPharmaceuticals announced announced that Peginterferon Lambda (Lambda) will be added to the ongoing,…

Read More Eiger announced Peginterferon Lambda added to multi-center phase 3 TOGETHER COVID-19 study in BrazilContinue

AIM ImmunoTech announced addition of single-agent Ampligen arm to Cancer Center’s study in cancer patients with COVID-19
COVID-19 | Life Science History

AIM ImmunoTech announced addition of single-agent Ampligen arm to Cancer Center’s study in cancer patients with COVID-19

On Mar. 22, 2021, AIM ImmunoTech announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer…

Read More AIM ImmunoTech announced addition of single-agent Ampligen arm to Cancer Center’s study in cancer patients with COVID-19Continue

Eiger announced ILIAD study results of peginterferon lambda in COVID-19 published in Lancet
COVID-19 | Life Science History

Eiger announced ILIAD study results of peginterferon lambda in COVID-19 published in Lancet

On Feb. 8, 2021, Eiger BioPharmaceuticals announced that the final results from the Phase 2 ILIAD (Interferon Lambda…

Read More Eiger announced ILIAD study results of peginterferon lambda in COVID-19 published in LancetContinue

AIM ImmunoTech announced patient dosed in study of Ampligen as combo treatment for patients with cancer and COVID-19
COVID-19 | Life Science History

AIM ImmunoTech announced patient dosed in study of Ampligen as combo treatment for patients with cancer and COVID-19

On Nov. 25, 2020, AIM ImmunoTech announced that Roswell Park Comprehensive Cancer Centerメs Phase 1/2a study evaluating the…

Read More AIM ImmunoTech announced patient dosed in study of Ampligen as combo treatment for patients with cancer and COVID-19Continue

Eiger announced positive results of randomized controlled trial with Peginterferon lambda in outpatients with COVID-19
COVID-19 | Life Science History

Eiger announced positive results of randomized controlled trial with Peginterferon lambda in outpatients with COVID-19

On Oct. 15, 2020, Eiger BioPharmaceuticals announced results of the ILIAD Study (Interferon Lambda for Immediate Antiviral Therapy…

Read More Eiger announced positive results of randomized controlled trial with Peginterferon lambda in outpatients with COVID-19Continue

Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | WHO

Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19

On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…

Read More Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19Continue

Eiger announced results of investigator sponsored study in outpatients with mild and uncomplicated COVID-19
COVID-19 | Life Science History

Eiger announced results of investigator sponsored study in outpatients with mild and uncomplicated COVID-19

On Sept. 28, 2020, Eiger BioPharmaceuticals announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in…

Read More Eiger announced results of investigator sponsored study in outpatients with mild and uncomplicated COVID-19Continue

AIM ImmunoTech announced start of recruitment in clinical trial incorporating Ampligen in treatment of cancer patients with COVID-19
COVID-19 | Life Science History

AIM ImmunoTech announced start of recruitment in clinical trial incorporating Ampligen in treatment of cancer patients with COVID-19

On Sept. 16, 2020, AIM ImmunoTech announced that recruitment had begun in Roswell Park Comprehensive Cancer Center’s Phase…

Read More AIM ImmunoTech announced start of recruitment in clinical trial incorporating Ampligen in treatment of cancer patients with COVID-19Continue

Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19
Biotechnology | COVID-19 | Diagnostics | Therapeutics

Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19

On Aug. 27, 2020, Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19 from our CLIA-certified laboratory….

Read More Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19Continue

NIH began clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment
COVID-19 | Life Science History

NIH began clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment

On Aug. 5, 2020, a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen…

Read More NIH began clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatmentContinue

AIM ImmunoTech announced FDA authorization for first human ampligen trial in COVID-19 patients with cancer
COVID-19 | FDA | Life Science History

AIM ImmunoTech announced FDA authorization for first human ampligen trial in COVID-19 patients with cancer

On May 14, 2020, AIM ImmunoTech announced the FDA authorized the first human trial assessing the safety and…

Read More AIM ImmunoTech announced FDA authorization for first human ampligen trial in COVID-19 patients with cancerContinue

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
COVID-19 | Life Science History

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

On Apr. 30, 2020, Eiger BioPharmaceuticals announced that the first patients have been dosed in a Phase 2…

Read More Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon LambdaContinue

Bayer partnered with Population Health Research Institute on global clinical research evaluating COVID-19 treatments
COVID-19 | Life Science History

Bayer partnered with Population Health Research Institute on global clinical research evaluating COVID-19 treatments

On Apr. 21, 2020, Bayer Mississauga, Ontario announced a partnership with the Population Health Research Institute (PHRI) to…

Read More Bayer partnered with Population Health Research Institute on global clinical research evaluating COVID-19 treatmentsContinue

Genentech drug Pegasys (peginterferon alfa-2a) approved
Biotechnology | Disease | FDA

Genentech drug Pegasys (peginterferon alfa-2a) approved

On Dec. 3, 2002, Genentech drug Pegasys (peginterferon alfa-2a) was approved by the Food and Drug Administration (FDA)…

Read More Genentech drug Pegasys (peginterferon alfa-2a) approvedContinue

The drug imatinib mesylate (Gleevec) was shown to be effective against chronic myelogenous leukemia
Biotechnology | Non-Profit Research | Oncology | Therapeutics

The drug imatinib mesylate (Gleevec) was shown to be effective against chronic myelogenous leukemia

In 2001, the drug imatinib mesylate (Gleevec) was shown in a clinical trial to be effective against chronic…

Read More The drug imatinib mesylate (Gleevec) was shown to be effective against chronic myelogenous leukemiaContinue

OMRF Scientists discovered Limitin, A new interferon-like substance
Biotechnology | Disease | Therapeutics

OMRF Scientists discovered Limitin, A new interferon-like substance

On Jun. 1, 2000, scientists at the Oklahoma Medical Research Foundation (OMRF) announced the discovery of a new…

Read More OMRF Scientists discovered Limitin, A new interferon-like substanceContinue

FDA approved Betaseron, the first of several biotech products that have had a major impact on multiple sclerosis treatment
FDA | Therapeutics

FDA approved Betaseron, the first of several biotech products that have had a major impact on multiple sclerosis treatment

On Jul. 23, 1993, the U.S. Food and Drug Administration (FDA) approved Betaseron, the first of several biotechnology…

Read More FDA approved Betaseron, the first of several biotech products that have had a major impact on multiple sclerosis treatmentContinue

Interferon became the first anticancer drug produced through biotechnology
Biotechnology | FDA | Oncology | Therapeutics

Interferon became the first anticancer drug produced through biotechnology

On Jun. 5, 1986, the U.S. Food and Drug Administration (FDA) approved Hoffmann La Roche’s Interferon  initially for…

Read More Interferon became the first anticancer drug produced through biotechnologyContinue

The first recombinant vaccine for humans, a vaccine for hepatitis B, was approved
Biotechnology | FDA | Life Science History | Therapeutics

The first recombinant vaccine for humans, a vaccine for hepatitis B, was approved

In May 1986, the vaccine Recombivax HB, which protects against hepatitis B infection, was approved for marketing in…

Read More The first recombinant vaccine for humans, a vaccine for hepatitis B, was approvedContinue

Discovery that treatment with human recombinant interferon gamma blocks the growth of T. gondii published
Biotechnology | Diagnostics | Infectious Disease | Therapeutics

Discovery that treatment with human recombinant interferon gamma blocks the growth of T. gondii published

On Feb. 8, 1984, Elmer R. Pfefferkorn published his discovery that treatment of human fibroblasts with human recombinant…

Read More Discovery that treatment with human recombinant interferon gamma blocks the growth of T. gondii publishedContinue

The first human testing of a biological therapy was conducted (alpha-interferon)
Biotechnology | Life Science History | Oncology | Therapeutics

The first human testing of a biological therapy was conducted (alpha-interferon)

On Nov. 9, 1978, the first human testing of a biological therapy was conducted (alpha-interferon). The Cancer Research…

Read More The first human testing of a biological therapy was conducted (alpha-interferon)Continue

Alick Isaacs and Jean Lindenmann discovered interferon, a virus fighter made by cells
Life Science History

Alick Isaacs and Jean Lindenmann discovered interferon, a virus fighter made by cells

In 1957, Alick Isaacs from Great Britain and Jean Lindenmann from Switzerland identified the interferons in 1957 and…

Read More Alick Isaacs and Jean Lindenmann discovered interferon, a virus fighter made by cellsContinue

  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search